Can-Fite BioPharma (CANF) announced that it received a single FDA approval for the compassionate use treatment of a U.S. based pancreatic cancer patient with its anti-cancer drug Namodenoson. Compassionate use is the term used when a physician is requesting for a single patient to gain access to an investigational drug for a serious disease.
Namodenoson is currently being evaluated in Liveration, a pivotal Phase III study for advanced liver cancer. Namodenoson has been also granted Orphan Drug Designation by the FDA for pancreatic cancer.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com